The treatment options for psoriatic arthritis (PsA) expanded significantly over the last decade and currently, twelve agents are approved for treatment of this disorder in the United States with moe approvals anticipated. While these agents provide a range of options for the treatment of PsA, they have not improved ACR responses compared to outcomes noted with anti-TNF agents reported twenty years ago. In contrast, treatment responses for psoriasis have shown great imrpovement with the advent of agents that block IL-17 of IL-23. Thus, the major challenge for rheumatologists is to devise strategies and therapies that will improve outcomes in PsA and elevate the frequency of remission.
Christopher Ritchlin, MD, MPH
Division Chief, Allergy, Immunology & Rheumatology
University of Rochester School of Medicine & Dentistry
Presented: 4/21/2021
20 апр 2021
